Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Bekaii-Saab Sheds Light on Furthering Biomarker-Driven Treatment in GI Cancers

January 26th 2020

Tanios S. Bekaii-Saab, MD, examines the effectiveness of umbrella trials and their importance in aiding precision medicine in gastrointestinal oncology.

High Responses Observed With Avelumab Added to Regimen for Metastatic Colorectal Cancer Does Not Translate to PFS

January 26th 2020

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

January 26th 2020

Peter R. Galle, MD, discusses the patient-reported outcomes results from the Phase III IMbrave150 study, which he presented at the 2020 Gastrointestinal Cancers Symposium

Dr. Wainberg on Impact of PD-L1 Status in Gastric/GEJ Cancer Treatment

January 26th 2020

Zev A. Wainberg, MD discusses the efficacy findings of pembrolizumab monotherapy versus chemotherapy for patients with PD-L1–positive advanced gastric and gastroesophageal junction cancer of high combined positive score in cohort 1 of the phase II KEYNOTE-059 and in the phase III KEYNOTE-061 and KEYNOTE-062 studies.

Kopetz Highlights Improved QoL, Efficacy With Encorafenib Regimens in BRAF+ mCRC

January 25th 2020

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC

January 25th 2020

The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.

Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer

January 25th 2020

The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation.

Frontline Lenvatinib with Subsequent Therapy Improves Survival in Unresectable HCC

January 25th 2020

Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Addition of Cabozantinib to Ipi/Nivo Shows Promising Antitumor Activity in Advanced HCC

January 25th 2020

The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.

Nivolumab/Ramucirumab Plus Chemo Highly Active in Second-Line Gastric Cancer

January 25th 2020

The triplet of nivolumab, ramucirumab and paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.

Dr. Macarulla Discusses Rapid Progressors in the POLO Trial

January 24th 2020

Teresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.

Larotrectinib Efficacy Confirmed in TRK+ GI Cancer

January 24th 2020

The efficacy of larotrectinib has been confirmed in patients with heavily pretreated TRK fusion–positive gastrointestinal cancers.

Pembrolizumab Shows Enhanced Efficacy in High PD-L1 Gastric Cancer

January 24th 2020

Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.

Dr. Cline on Data With PARP Inhibitors in Pancreatic Cancer

January 23rd 2020

Mika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.

Dr. Abou-Alfa on Ramucirumab as Second-Line Therapy for Hepatocellular Carcinoma

January 23rd 2020

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers

January 22nd 2020

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Surufatinib Improves PFS in Advanced Pancreatic Neuroendocrine Tumors

January 22nd 2020

Surufatinib improved progression-free survival compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors for whom there is no effective therapy.

Dr. Ribeiro on the Role of Surgery in Pancreatic Cancer

January 22nd 2020

Afonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.

FDA Grants Durvalumab Plus Tremelimumab Orphan Drug Status in HCC

January 22nd 2020

The FDA has granted an orphan drug designation to durvalumab and tremelimumab for the treatment of patients with hepatocellular carcinoma.